Is the prognosis of heart failure improving?

[1]  S G Thompson,et al.  Survival of patients with a new diagnosis of heart failure: a population based study , 2000, Heart.

[2]  J. Cleland,et al.  Is the prognosis of heart failure improving? , 1999, Journal of the American College of Cardiology.

[3]  J. Gore,et al.  Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective. , 1999, Journal of the American College of Cardiology.

[4]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.

[5]  D. Levy,et al.  Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. , 1999, Journal of the American College of Cardiology.

[6]  N Freemantle,et al.  The evidence for β blockers in heart failure , 1999, BMJ.

[7]  J. Cleland,et al.  Has the survival of the heart failure population changed? Lessons from trials. , 1999, The American journal of cardiology.

[8]  S G Thompson,et al.  Incidence and aetiology of heart failure; a population-based study. , 1999, European heart journal.

[9]  Richard W. Lee,et al.  Sympathetic Activation in Heart Failure and Its Treatment With β-Blockade , 1999 .

[10]  K. Bailey,et al.  Congestive heart failure in the community: trends in incidence and survival in a 10-year period. , 1999, Archives of internal medicine.

[11]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[12]  N. Freemantle,et al.  Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. , 1999, European journal of heart failure.

[13]  G. S. Pepper,et al.  Sympathetic activation in heart failure and its treatment with beta-blockade. , 1999, Archives of internal medicine.

[14]  K. Bailey,et al.  Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. , 1998, Circulation.

[15]  J. Cleland.  Heart failure: a medical hydra , 1998, The Lancet.

[16]  J. Cleland,et al.  Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? , 1998, European heart journal.

[17]  D. Vaughan,et al.  Angiotensin-converting enzyme inhibitors. , 1998, Circulation.

[18]  R. Starling.  Radical alternatives to transplantation , 1998 .

[19]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[20]  K. Bailey,et al.  Congestive Heart Failure in the Community , 1998 .

[21]  B. Massie,et al.  Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. , 1997, American heart journal.

[22]  D E Grobbee,et al.  The epidemiology of heart failure. , 1997, European heart journal.

[23]  G. Hillis,et al.  Changing patterns of investigation and treatment of cardiac failure in hospital. , 1996, Heart.

[24]  E. Philbin,et al.  Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. , 1996, The American journal of cardiology.

[25]  G. Hillis,et al.  Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence? , 1996, QJM : monthly journal of the Association of Physicians.

[26]  F. Mair,et al.  Prevalence, aetiology and management of heart failure in general practice. , 1996, The British journal of general practice : the journal of the Royal College of General Practitioners.

[27]  B. Kinosian,et al.  Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. , 1995, Journal of cardiac failure.

[28]  L. Køber,et al.  Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. , 1995, The American journal of cardiology.

[29]  J. Cleland.  ACE inhibitors for the prevention and treatment of heart failure: why are they 'under-used'? , 1995, Journal of human hypertension.

[30]  K. Bailey,et al.  The incidence and prevalence of congestive heart failure in Rochester, Minnesota. , 1993, Mayo Clinic proceedings.

[31]  B. Massie,et al.  Congestive heart failure: insights from epidemiology, implications for treatment. , 1993, Mayo Clinic proceedings.

[32]  D. Levy,et al.  The epidemiology of heart failure: the Framingham Study. , 1993, Journal of the American College of Cardiology.

[33]  D. Levy,et al.  Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.

[34]  M. Packer.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[35]  P. Poole‐Wilson,et al.  Prevalence of heart failure in three general practices in north west London. , 1992, The British journal of general practice : the journal of the Royal College of General Practitioners.

[36]  J. Remes,et al.  Incidence of heart failure in eastern Finland: a population-based surveillance study. , 1992, European heart journal.

[37]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[38]  L Wilhelmsen,et al.  Risk factors for heart failure in the general population: the study of men born in 1913. , 1989, European heart journal.

[39]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.